Cronos Group Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; filed February 26, 2021. Amounts are U.S. dollars unless stated otherwise. This is an annual report, not a standalone fourth-quarter filing; the supplied text does not provide a clear set of Q4 financial results.
Business context
Cronos is a cannabinoid company reporting two segments: Rest of World, principally cannabis operations, and United States, principally hemp-derived CBD products. Brands include PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. The company sells across Canada and selected international markets and does not conduct U.S. Schedule I cannabis activities.
Financial results and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Net revenue, after excise taxes | $46.7 million | $23.8 million |
| Revenue before excise taxes | $54.4 million | $25.6 million |
| Gross profit (loss) | $(25.8) million | $(17.6) million |
| Gross margin | (55)% | (74)% |
| Operating loss | $(179.3) million | $(121.1) million |
| Net income (loss) | $(75.3) million | $1,165.6 million |
| Adjusted EBITDA (non-GAAP) | $(147.3) million | $(98.3) million |
| Cash used in operating activities | $(142.5) million | $(130.3) million |
- Revenue rose 97%, reflecting Canadian adult-use growth and Israeli medical-market sales, plus a full year of Redwood results versus 117 days in 2019. Canadian strategic price reductions and non-recurring 2019 wholesale sales partly offset growth.
- Gross loss worsened despite lower inventory write-downs: FY 2020 write-downs were $26.1 million versus $29.2 million in 2019. Higher cost of third-party cannabis flower and weaker wholesale sales pressured Rest of World margins. Management cautioned further inventory write-downs may occur.
- Rest of World revenue was $37.2 million, up 83%; Adjusted EBITDA was $(98.3) million. U.S. revenue was $9.5 million, up 182%, while Adjusted EBITDA declined to $(28.0) million; U.S. gross margin fell to 44% from 56%.
- FY 2019 net income was dominated by a $1.277 billion gain on revaluation of Altria-related derivative liabilities. The corresponding 2020 gain was $129.3 million, so headline net income comparisons are not indicative of operating improvement. FY 2020 also included $40.0 million of goodwill and intangible impairment and $9.7 million of restatement-related review and legal costs.
- Year-end cash and cash equivalents were $1.078 billion and short-term investments $211.8 million, about $1.29 billion combined. Current assets were $1.372 billion versus current liabilities of $206.8 million. The company reported no external financing or loans payable; lease obligations remain. Derivative liabilities were $163.4 million.
- Net cash used in investing activities was $20.2 million, while financing used $5.5 million. Capital expenditures for property and equipment were $31.4 million. Management said available cash and short-term investments should fund operations and capital expenditures for at least 12 months.
Material changes and developments
- COVID-19 and retail closures slowed U.S. revenue growth and contributed to second-quarter impairments of $35 million against U.S. reporting-unit goodwill and $5 million against the Lord Jones brand. Management reported no additional U.S. impairment in Q4. It said Rest of World revenue was not materially affected for the full year, but Canadian near-term growth could be pressured.
- Happy Dance launched in Q4 2020; its products were online, with a planned expansion to more than 550 ULTA locations. PEACE+ products remained in development and were not yet for sale.
- Cronos GrowCo completed construction and obtained a first-phase cultivation license in November 2020; phased operations were expected to begin in the first half of 2021, subject to further approvals. Cronos Israel began Israeli medical-market distribution in Q2 2020. Natuera made its first commercial export of hemp-derived CBD extract to the U.S.
- The company advanced plans to sell substantially all OGBC assets. OGBC was classified as held for sale/discontinued operations; the filing does not say the sale was completed. It recorded $1.86 million of held-for-sale asset losses, including a further $941,000 in Q4 after surrender of OGBC Health Canada licenses.
- Altria beneficially owned about 43.5% of shares at year-end and held an unexercised warrant for up to approximately 80.1 million additional shares, exercisable through March 8, 2023. Exercise could give Altria majority control and materially dilute other shareholders.
Outlook, risks and contingencies
- No quantified revenue, profit, margin or cash-flow guidance was provided. Management emphasized execution of its brand, distribution, supply-chain and cannabinoid R&D strategy. Commercial production from the Ginkgo partnership remained dependent on strains, licenses and milestones; the first equity milestone was expected by Q3 2021.
- Key risks include ongoing operating losses and cash burn, Canadian cannabis price compression and oversupply, reliance on provincial buyers, customer concentration, and uncertainty over evolving cannabis and U.S. hemp/CBD regulation. Four Canadian provincial customers represented approximately 63% of revenue before excise taxes; each was individually above 10%.
- COVID-19-related store closures, supply disruptions, product shortages and changes in consumer spending could continue to affect demand and operations. The U.S. CBD business faces particular FDA and state-law uncertainty, including restrictions on CBD in foods and dietary supplements and possible enforcement over product claims or classification.
- A Canadian class action alleges inaccurate cannabinoid content in products and seeks C$500 million plus C$5 million in punitive damages against each defendant, including Cronos; the company had not responded to the amended claim as of the filing. Separate U.S. and Canadian shareholder class actions and regulatory reviews relate to the 2019 interim financial-statement restatement; outcomes are uncertain.
- KPMG issued an unqualified opinion on the financial statements but an adverse opinion on internal control over financial reporting. A year-end material weakness involved inventory verification: excluded inventory exceeded materiality thresholds and count, transcription and reconciliation errors caused inaccurate adjustments. Management said the weakness did not result in quantitatively material errors and outlined enhanced counts, cycle counts and training. Disclosure controls were also deemed ineffective.
Most important facts for investors to verify
- Whether the inventory-control remediation is implemented and operating effectively, and whether subsequent filings identify inventory adjustments or restatements.
- Actual progress and economics of GrowCo operations, the OGBC asset sale, and Ginkgo commercialization versus management’s stated expectations.
- Whether Canadian price pressure, inventory write-downs and negative gross margins improve, and how quickly revenue growth translates into reduced operating cash burn.
- Developments in the CBD regulatory environment, COVID-19 impacts, and the outcomes or potential exposure from the cannabinoid-content class action and restatement-related proceedings.
- Potential dilution and governance implications of Altria warrant, pre-emptive and top-up rights, as well as the company’s deployment of its substantial cash balance.